Clavis Pharma appoints chief business officer

Nicholas Adams takes the role at Norwegian firm

Clavis Pharma, a Norwegian cancer drug development company, has appointed Nicholas Adams as chief business officer. He replaces Jan Alfheim, who has become managing director of Nordic Nanovector.

For the past 12 years, Adams worked for the UK cancer company, Antisoma plc, the majority of the time as vice president business development and a member of the senior management team.

Prior to this, he spent 11 years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance.

Olav Hellebø, ceo of Clavis Pharma, said Adams brings to the company considerable experience in business development, particularly in building partnerships with leading pharmaceutical companies, and with a strong focus in oncology.

You may also like

Regulatory

Anticancer agent – elacytarabine

Cytarabine can cross the blood–brain barrier and is useful in the treatment of CNS lymphomas, but the response is variable and resistance commonly develops
Regulatory

Leukaemia treatment gains fast track designation

Clavis Pharma’s elacytarabine currently in Phase III trial
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development

NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing

The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development

Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme

The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Manufacturing

Precision meets innovation in melting point determination

Advancing analytical accuracy with automated thermal analysis
Subscribe now